Table 4.

Overall survival and disease free survival between SKP2 expression and survival difference attenuation by overexpression of tumoral FOXP3 expression, Beclin-1 expression and Tregs infiltration.

	Positive SKP2 expression		Negative SKP2 expression
Overall survival	Mean (months)	95% CI	Mean (months)	95% CI	P
Tumoral FOXP3 expression
High	110.2	102.8 to 117.6	105.9	93.0 to 118.8	.475
Low	94.2	82.5 to 105.9	85.7	73.5 to 97.9	.050
Beclin-1 expression
High	108.3	101.6 to 114.9	109.2	99.0 to 119.3	.733
Low	98.8	78.1 to 119.5	79.7	65.7 to 93.8	.153
Tregs count
≥15/HPFs	107.7	99.6 to 115.7	106.9	94.8 to 118.9	.423
<15/HPFs	105.0	94.4 to 115.6	85.6	73.0 to 98.2	.020∗

	Positive SKP2 expression		Negative SKP2 expression
Disease-free survival	Mean (months)	95% CI	Mean (months)	95% CI	P
Tumoral FOXP3 expression
High	110.9	103.4 to 118.6	105.6	92.4 to 118.8	.419
Low	100.0	90.6 to 109.4	75.8	63.2 to 88.5	.001∗
Beclin-1 expression
High	110.7	104.6 to 116.7	104.3	92.7 to 115.9	.123
Low	103.9	84.3 to 123.4	71.8	57.6 to 86.1	.037∗
Tregs count
≥15/HPFs	N.A	N.A	N.A	N.A	.010∗
<15/HPFs	N.A	N.A	N.A	N.A	.008∗